| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-09-30 |
|---|---|---|---|---|
| Total other income (expense), net | 6,880 | -7,931 | 62,323 | -8,969 |
| Net loss | -17,510 | -37,658 | 39,139 | -39,202 |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -0.11 | -0.24 | 0.28 | -0.33 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -0.11 | -0.24 | 0.28 | -0.33 |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic (in shares) | 158,313,290 | 155,437,281 | 131,496,877 | 119,408,565 |
| Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, diluted (in shares) | 158,313,290 | 155,437,281 | 131,759,302 | 119,408,565 |
Humacyte, Inc. (HUMA)
Humacyte, Inc. (HUMA)